NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
- Phase 1b updates for NC410 and NC762, and operational update for NC525 Phase 1a are expected by year end
- Cash of approximately
$118 millionexpected to fund operations into mid-2025
“We plan to provide updates on our clinical programs, including the Phase 1b trial of NC410 in combination with pembrolizumab in patients with solid tumors, the Phase 1b trial of NC762 targeting tumor types with high B7-H4 expression, and a Phase 1a operational update for NC525 treating patients with acute myeloid leukemia (AML) by the end of the year,” said
Q3 2023 Business Highlights and Updates
- Phase 1b updates for NC410 (LAIR-2 Fusion) and NC762 (B7-H4 mAb) by year end.
- Operational update for NC525 (LAIR-1 mAb) Phase 1a by year end.
- Selected LNCB74 (B7-H4 ADC), the first antibody drug conjugate (ADC) candidate from our collaboration with LegoChem Biosciences, Inc. Under the terms of the collaboration, both parties equally share the costs of developing the molecules and profits on commercialized products.
- Presented data on NC605, a novel anti-Siglec-15 antibody, at the
American Society for Bone and Mineral Research(ASBMR) Annual Meeting, demonstrating reduced bone loss and enhanced bone quality in mice with osteogenesis imperfecta.
- Presented data on NC181, a novel humanized antibody targeting ApoE4, at the 2023
Cambridge Health Tech Institute's2nd Annual Neurodegeneration Targets Conference, demonstrating amyloid clearance, prevention of amyloid deposition, plaque clearance and other important findings for the treatment of Alzheimer’s disease.
- NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditures into mid-2025.
Financial Results for Quarter Ended
- Cash, cash equivalents, and marketable securities as of
September 30, 2023, were $118.2 millionas compared to $159.9 millionas of December 31, 2022. The decrease of $41.7 millionwas primarily related to cash used to fund operations, and cash used to purchase fixed assets.
- Research and development expenses were
$11.0 millionfor the quarter ended September 30, 2023, as compared to $13.5 millionfor the quarter ended September 30, 2022. The decrease of $2.5 millionwas primarily related to lower costs related to our clinical programs.
- General and administrative expenses were
$4.6 millionfor the quarter ended September 30, 2023, as compared to $5.7 millionfor the quarter ended September 30, 2022. The decrease of $1.1 millionwas primarily related to lower payroll related costs, lower stock compensation, lower insurance costs and lower legal costs.
- Net loss was
$14.3 millionfor the quarter ended September 30, 2023, as compared with a net loss of $18.9 millionfor the quarter ended September 30, 2022. Lower research and development expenses, lower general and administrative expenses and higher other income contributed to the lower net loss.
Some of the statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to funding for our operations, objectives and expectations for our business, operations and financial performance and condition, including the progress and results of clinical trials, development plans and upcoming milestones regarding our immunomedicines. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “should,” “due,” “estimate,” “expect,” “intend,” “hope,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “target,” “towards,” “forward,” “later,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language.
Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure’s limited operating history and not having any products approved for commercial sale; NextCure’s history of significant losses; NextCure’s need and ability to obtain additional financing on acceptable terms or at all; risks related to clinical development, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on NextCure’s FIND-IO platform; and NextCure’s dependence on key personnel. More detailed information on these and additional factors that could affect NextCure’s actual results are described under the heading “Risk Factors” in NextCure’s most recent Annual Report on Form 10-K and in NextCure’s other filings with the
|Selected Financial Information|
|Selected Statement of Operations Items:||Three Months Ended||Nine Months Ended|
|(in thousands, except share and per share amounts)||2023||2022||2023||2022|
|Research and development||$||11,010||$||13,528||$||36,104||$||41,377|
|General and administrative||4,608||5,711||15,743||16,761|
|Loss from operations||(15,618||)||(19,239||)||(51,847||)||(58,138||)|
|Other income, net||1,317||328||3,591||705|
|Net loss per common share - basic and diluted||$||(0.51||)||$||(0.68||)||$||(1.73||)||$||(2.07||)|
|Weighted-average shares outstanding - basic and diluted||27,839,968||27,748,844||27,814,655||27,734,271|
|Selected Balance Sheet Items:|
|Cash, cash equivalents, and marketable securities||$||118,206||$||159,911|
|Accounts payable and accrued liabilities||$||6,552||$||9,127|
|Total stockholders' equity||$||126,452||$||167,530|
Chief Operating Officer